- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02273193
Utility Of Hemoglobin A1C For The Diagnosis Of Gestational Diabetes (A1cGDM)
Utility Of Hemoglobin A1C (HbA1C) For The Diagnosis Of Gestational Diabetes Mellitus (GDM).
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This is a prospective cohort research study conducted in the Mike O'Callaghan Federal Medical Center (MOFMC), Department of Family Medicine Residency and Obstetrics Clinics. Subjects will be pregnant female active duty or DoD beneficiaries 18 years or older recruited from the MOFMC, Department of Family Medicine Residency Clinic, and Obstetrics Orientation Class at Nellis AFB. At the screening, the Research Assistant discusses the study, answers all questions, obtains Informed Consent, and schedules appointments for routine OB care. The research design includes a screening visit to obtain written consent and two (2) additional laboratory blood tests obtained during the standard of care prenatal screen testing during the first and second trimesters of pregnancy. Each laboratory blood test will be done via 1 venipuncture for 5-10 ml (1-2 teaspoons) of blood. The OB nurse orders all labs upon completion of the Obstetrics Orientation Class.
Screening Visit: Initial Standard of Care Obstetrics Appointment
- Obtain subject signed Informed Consent document and HIPAA Authorization
- Demographic data: age, race, weight, height, estimated week of gestation
- Review past medical history
First Trimester Prenatal Visit (<13 weeks) Screen Testing
- Subjects will have routine prenatal labs drawn to include the HbA1C blood test which is standard of care
- Subjects will have fasting (10 hour) glucose blood test will be ordered along with these labs (research driven)
Second Trimester Prenatal Visit (24-28 weeks)
- Subjects will have routine prenatal labs drawn to include the 2 hr glucose tolerance test (2 hr OGTT) which is standard of care
- Subjects will have will be the HbA1C blood test ordered along with these labs (research driven)
Delivery and Neonatal Data Collection
-Select data regarding delivery and neonatal health will be tracked. All of this data is already routinely collected as standard of care and will be found in the patient record. This will require no interaction with the patient or the neonate
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Nevada
-
Nellis Air Force Base, Nevada, États-Unis, 89191
- Mike O'Callaghan Federal Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE IN ORDER TO PARTICIPATE IN THIS STUDY.
Inclusion:
- Active duty or DoD beneficiaries of childbearing age 18 years or older with a positive pregnancy test (beta human chorionic gonadotropin).
Exclusion:
Active duty or DoD beneficiaries of childbearing age 18 years or older with a positive pregnancy test (beta human chorionic gonadotropin) known to have and/or develop during the study any of the following upon review of their medical record:
- Hemoglobinopathy (including sickle cell disease or trait, thalassemia)
- Chronic kidney disease
- Diabetes
- Active duty or DoD beneficiaries of childbearing age 18 years or older with a positive pregnancy test (beta human chorionic gonadotropin) taking any of the following:
- Erythropoietin
- Daily oral steroids
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cas-témoins
- Perspectives temporelles: Éventuel
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Pregnant Women
Pregnant Women in the first trimester (<13 weeks) of pregnancy and the second trimester of pregnancy.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Fasting Glucose will be obtained during the first trimester of pregnancy
Délai: 13 weeks
|
13 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Hemoglobin A1c will be obtained during the second trimester of pregnancy (between 24-28 weeks)
Délai: 24-28 weeks
|
24-28 weeks
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- FWH20130041H
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .